JP2020516663A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516663A5
JP2020516663A5 JP2019556183A JP2019556183A JP2020516663A5 JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5 JP 2019556183 A JP2019556183 A JP 2019556183A JP 2019556183 A JP2019556183 A JP 2019556183A JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5
Authority
JP
Japan
Prior art keywords
dihydronaphthalene
dioxo
methoxy
methylidene
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027786 external-priority patent/WO2018194976A1/en
Publication of JP2020516663A publication Critical patent/JP2020516663A/ja
Publication of JP2020516663A5 publication Critical patent/JP2020516663A5/ja
Pending legal-status Critical Current

Links

JP2019556183A 2017-04-17 2018-04-16 炎症によって誘起されるdna損傷の阻止及び回復 Pending JP2020516663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486033P 2017-04-17 2017-04-17
US62/486,033 2017-04-17
PCT/US2018/027786 WO2018194976A1 (en) 2017-04-17 2018-04-16 Prevention and reversal of inflammation induced dna damage

Publications (2)

Publication Number Publication Date
JP2020516663A JP2020516663A (ja) 2020-06-11
JP2020516663A5 true JP2020516663A5 (https=) 2021-04-30

Family

ID=63856081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556183A Pending JP2020516663A (ja) 2017-04-17 2018-04-16 炎症によって誘起されるdna損傷の阻止及び回復

Country Status (5)

Country Link
US (2) US20190117602A1 (https=)
EP (1) EP3440047A4 (https=)
JP (1) JP2020516663A (https=)
CA (1) CA3060266A1 (https=)
WO (1) WO2018194976A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
JP7266304B2 (ja) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
EP3897601A4 (en) * 2018-12-17 2022-08-31 Indiana University Research And Technology Corporation TREATMENT OF GASTROINTESTINAL DISEASES AND THEIR SYMPTOMS
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
CN119097711A (zh) * 2024-09-11 2024-12-10 山东大学齐鲁医院 Ape1抑制剂在制备治疗鼻窦炎药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801949A1 (en) * 1996-04-15 1997-10-22 Eisai Co., Ltd. Hypoglycemic quinone derivative
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
EP0813866A3 (en) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutic agent for joint diseases
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
AU2008304619C1 (en) * 2007-09-26 2020-06-04 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
KR20110103442A (ko) 2008-12-23 2011-09-20 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 염증 표적화 입자
GB201020397D0 (en) 2010-12-02 2011-01-12 Univ Nottingham Compounds
WO2012148889A1 (en) 2011-04-28 2012-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human apurinic/apyrimidinic endonuclease 1
KR101982669B1 (ko) * 2011-05-26 2019-05-27 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ape1 매개된 질환을 치료하기 위한 퀴논 화합물
US20140128398A1 (en) * 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
CN107184572B (zh) 2017-03-09 2020-07-28 中山大学 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用

Similar Documents

Publication Publication Date Title
JP2020516663A5 (https=)
JP2020533315A5 (https=)
JP2019536805A5 (https=)
HRP20220619T1 (hr) Postupci za liječenje ar+ raka dojke
JP2018514549A5 (https=)
JP2016513097A5 (https=)
JP2014532647A5 (https=)
JP2008519047A5 (https=)
JP2017528507A5 (https=)
JP2019508476A5 (https=)
JP2007536311A5 (https=)
JP2016515586A5 (https=)
JP2021080296A5 (https=)
RU2010151660A (ru) Способы лечения множественной миеломы
JP2019522032A5 (https=)
RU2020109376A (ru) Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени
JP2023525100A5 (https=)
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
Gupta et al. Combating inadequate anesthesia in periapical infections, with sodium bicarbonate: a clinical double blind study
JP2005505539A (ja) パーキンソン病の治療のためのcb1受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物
JP2020529995A5 (https=)
JP2006502132A5 (https=)
Koh et al. Use of hyaluronidase as an adjuvant to ropivacaine to reduce axillary brachial plexus block onset time: a prospective, randomised controlled study
Chia et al. The efficacy of thoracic epidural neostigmine infusion after thoracotomy
JP2015522077A5 (https=)